Nian-guang G. Li

138 Xianlin Road
Nanjing, 210023, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 56 publications

Discovery of FYJ-195 as a Highly Potent FLT3 Inhibitor against Multiple Acquired Resistance Mutations in Acute Myeloid Leukemia.

Discovery of FYJ-195 as a Highly Potent FLT3 Inhibitor against Multiple Acquired Resistance Mutations in Acute Myeloid Leukemia.

Journal: Journal of medicinal chemistry

Published: May 23, 2026

Discovery of CN-3 as a Next-Generation RET Inhibitor Potently Overcoming Multiple Mutations.

Discovery of CN-3 as a Next-Generation RET Inhibitor Potently Overcoming Multiple Mutations.

Journal: Journal of medicinal chemistry

Published: May 02, 2026

Discovery of FLC-8 as the First Covalent FLT3 Inhibitor Targeting Cys807 for FLT3 Mutant Acute Myeloid Leukemia.

Discovery of FLC-8 as the First Covalent FLT3 Inhibitor Targeting Cys807 for FLT3 Mutant Acute Myeloid Leukemia.

Journal: Journal of medicinal chemistry

Published: April 03, 2026

Fluorescence polarization-based discovery of natural RORγ orthosteric inhibitors.

Fluorescence polarization-based discovery of natural RORγ orthosteric inhibitors.

Journal: European journal of medicinal chemistry

Published: January 06, 2026

Synthesis and biological evaluation of C-28-modified pyrazole-fused betulinic acid derivatives as potent antiosteoporosis agents.

Synthesis and biological evaluation of C-28-modified pyrazole-fused betulinic acid derivatives as potent antiosteoporosis agents.

Journal: European journal of medicinal chemistry

Published: June 18, 2025

RETRACTED: Yue et al. A Ferulic Acid Derivative FXS-3 Inhibits Proliferation and Metastasis of Human Lung Cancer A549 Cells via Positive JNK Signaling Pathway and Negative ERK/p38, AKT/mTOR and MEK/ERK Signaling Pathways. Molecules 2019, 24, 2165.

RETRACTED: Yue et al. A Ferulic Acid Derivative FXS-3 Inhibits Proliferation and Metastasis of Human Lung Cancer A549 Cells via Positive JNK Signaling Pathway and Negative ERK/p38, AKT/mTOR and MEK/ERK Signaling Pathways. Molecules 2019, 24, 2165.

Journal: Molecules (Basel, Switzerland)

Published: April 30, 2025

MALT1 Inhibitors and Degraders: Strategies for NF-κB-Driven Malignancies.

MALT1 Inhibitors and Degraders: Strategies for NF-κB-Driven Malignancies.

Journal: Journal of medicinal chemistry

Published: February 25, 2025

Design, Synthesis, and Biological Evaluation of 3,4-Dihydroisoquinolin-1(2H)-one Derivatives as Protein Arginine Methyltransferase 5 Inhibitors for the Treatment of Non-Hodgkin's Lymphoma.

Design, Synthesis, and Biological Evaluation of 3,4-Dihydroisoquinolin-1(2H)-one Derivatives as Protein Arginine Methyltransferase 5 Inhibitors for the Treatment of Non-Hodgkin's Lymphoma.

Journal: Journal of medicinal chemistry

Published: December 26, 2024

Kinase-Bench: Comprehensive Benchmarking Tools and Guidance for Achieving Selectivity in Kinase Drug Discovery.

Kinase-Bench: Comprehensive Benchmarking Tools and Guidance for Achieving Selectivity in Kinase Drug Discovery.

Journal: Journal of chemical information and modeling

Published: December 02, 2024

Discovery of 1-(Phenylsulfonyl)-1,2,3,4-tetrahydroquinoline Derivative as Orally Bioavailable and Safe RORγt Inverse Agonists for Potential Treatment of Rheumatoid Arthritis.

Discovery of 1-(Phenylsulfonyl)-1,2,3,4-tetrahydroquinoline Derivative as Orally Bioavailable and Safe RORγt Inverse Agonists for Potential Treatment of Rheumatoid Arthritis.

Journal: Journal of medicinal chemistry

Published: November 15, 2024

Metabolite Profiling of Danatinib in Mice Using Ultra-High-Performance Liquid Chromatography/Tandem Mass Spectrometry In Vitro and In Vivo.

Metabolite Profiling of Danatinib in Mice Using Ultra-High-Performance Liquid Chromatography/Tandem Mass Spectrometry In Vitro and In Vivo.

Journal: Biomedical chromatography : BMC

Published: September 29, 2024

Discovery of SILA-123 as a Highly Potent FLT3 Inhibitor for the Treatment of Acute Myeloid Leukemia with Various FLT3 Mutations.

Discovery of SILA-123 as a Highly Potent FLT3 Inhibitor for the Treatment of Acute Myeloid Leukemia with Various FLT3 Mutations.

Journal: Journal of medicinal chemistry

Published: September 11, 2024

Showing 1-12 of 56

Last Updated: 09/26/2026